Loading the company…
Loading the company…
In 2025, Atricure reported engagement with 10,821 surgeons and other clinicians in the states MedaRep covers, worth $4.7M in consulting, speaking, meals and travel for its device products, the most in Florida ($708K to 1,241). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($708K, 1,241 engaged), California ($549K, 845 engaged), Ohio ($362K, 691 engaged), Kentucky ($238K, 279 engaged), Wisconsin ($237K, 142 engaged).
In the last ten years FDA made 1 decision for Atricure (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2018 (1). The latest was on 2018-02-15.
| Family | Decisions on record |
|---|---|
| Tumor ablation | 8 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2018-02-15 | 510(k) | K180137 | AtriCure cryoICE cryo-ablation probe (CRYO3), AtriCure cryoICE cryoFORM cryo-ablation probe (CRYOF) |
| 2016-03-22 | 510(k) | K152337 | cryoFORM cryoICE cryoablation probe |
| 2014-10-29 | 510(k) | K142441 | cryoICE croablation probe |
| 2014-01-24 | 510(k) | K140058 | ATRICURE CRYO MODULE SYSTEM |
| 2012-06-06 | 510(k) |
| K121507 |
| ATRICURE CRYO MODULE SYSTEM (ACM, CRYO1, AND CRYOICE) |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Atricure.